Patents by Inventor Antonin DeFougerolles

Antonin DeFougerolles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE
    Publication number: 20210155937
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Application
    Filed: July 7, 2020
    Publication date: May 27, 2021
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • Compositions and methods for inhibiting expression of CD274/PD-L1 gene
    Patent number: 10745704
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: August 18, 2020
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE
    Publication number: 20190048352
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Application
    Filed: February 27, 2018
    Publication date: February 14, 2019
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • Compositions and methods for inhibiting expression of CD274/PD-L1 gene
    Patent number: 9932593
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: April 3, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE
    Publication number: 20170067060
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Application
    Filed: July 18, 2016
    Publication date: March 9, 2017
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • Compositions and methods for inhibiting expression of CD274/PD-L1 gene
    Patent number: 9422562
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: August 23, 2016
    Assignee: Alnylam Pharmaceuticals
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE
    Publication number: 20140148497
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Application
    Filed: July 10, 2013
    Publication date: May 29, 2014
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • Compositions and methods for inhibiting expression of CD274/PD-L1 gene
    Patent number: 8507663
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: August 13, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin Defougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE
    Publication number: 20110251259
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Application
    Filed: April 6, 2011
    Publication date: October 13, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • Method for the treatment of inflammatory disorders
    Patent number: 7462353
    Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
    Type: Grant
    Filed: April 18, 2005
    Date of Patent: December 9, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Philip Gotwals, Antonin DeFougerolles, Roy Lobb, Victor Koteliansky
  • Method for the treatment of inflammatory disorders
    Patent number: 6955810
    Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: October 18, 2005
    Assignee: Biogen Idec, Inc.
    Inventors: Philip Gotwals, Antonin DeFougerolles, Roy Lobb, Victor Kotelianski
  • Method for the treatment of inflammatory disorders
    Publication number: 20050226877
    Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
    Type: Application
    Filed: April 18, 2005
    Publication date: October 13, 2005
    Applicant: BIOGEN IDEC, INC.
    Inventors: Philip Gotwals, Antonin DeFougerolles, Roy Lobb, Victor Kotelianski
  • Global expression analysis of extracellular matrix-integrin interactions in monocytes
    Publication number: 20030124726
    Abstract: Disclosed are methods of identifying integrin modulating agents using differential gene expression. Also disclosed are method of treating atheroscerosis and inflammatory disorders in a subject.
    Type: Application
    Filed: August 3, 2001
    Publication date: July 3, 2003
    Inventors: Antonin deFougerolles, Philip Gotwals, Cynthia Green, Victor Koteliansky